Background Monitoring the trends of pre-treatment drug resistance (PDR) and resistance-
associated mutations (RAMs) among antiretroviral-naïve people with HIV (PWH) is important …

Sir, HIV-1 transmitted drug resistance (TDR) can impair the first-line antiretroviral therapy
response. Moreover, minority resistant variants (MRVs) can be a source of virological failure …

Objectives: Integrase strand-transfer inhibitor (InSTI)-based regimens are the preferred
combinations for naïve HIV-infected individuals. Polymorphic substitutions that reduce …

The currently approved integrase strand transfer inhibitors (INSTIs), raltegravir (RAL) and
elvitegravir (EVG) effectively halt HIV-1 replication but their use is limited by their low genetic …

Objectives To define whether the prevalence of mutations associated with integrase inhibitor
(INI) resistance is different in untreated versus antiretroviral-treated HIV-1-infected …

The present study investigated prevalence of integrase strand transfer inhibitors (INSTI)
resistance mutations in HIV-1-infected antiretroviral therapy (ART)-naïve patients in Korea …

Integrase inhibitor (INI) is a novel antiretroviral drug recommended for both treatment-naive
and treatment-experienced HIV-1-infected patients. Limited data are available on INI …

Abstract Background In China, the recommended treatment regimens for HIV-infected
individuals were tenofovir in combination with lamivudine or emtricitabine as NRTIs …

Background INSTIs have become a pillar of first-line ART. Real-world data are needed to
assess their effectiveness in routine care. Objectives We analysed ART-naive patients who …

Objectives We evaluated variant-associated variability at positions related to resistance to
the integrase (IN) inhibitors (INIs) raltegravir, elvitegravir and dolutegravir using HIV-1 IN …